951950-33-7

MLN4924 has been used as a neddylation inhibitor:

• to tre at cell lines stably expressing a GaLV/MLV chimera construct in order to study its effects on viral transduction and infectivity
• to study its effects on the accumulation of LCMT1, suggesting a potential role in regulating LCMT1 stability and degradation in LNCaP cells
• to study UBX-390-mediated degradation of androgen receptor (AR) via proteasomal action in a prostate cancer cell line

A cell-permeable AMP mimetic that targets the NEDD8-activating E1 enzyme NAE nucleotide-binding site and undergoes a NAE-catalyzed covalent NEDD8 adduct formation, the adduct in turn acts as a tight-binding, ATP-competitive NAE inhibitor (IC₅₀ = 4.7 nM), exhibiting much reduced or little potency against UAE/UBA1, UBA6/UBE1L2, SAE, ATG7, adenosine receptors A₁/A_2A/A_2B/A₃, or a panel of 12 cellular kinases. Selectively reduces cellular Ubc12-NEDD8, but not Ubc9-SUMO or Ubc10-Ub, thioester formation (IC_max = 90 nM in HCT-116 cultures in 24 h), resulting in cullin-RING ligases substrates elevation. Shown to inhibit the growth of various cancer cells both in cultures (IC₅₀ from 50 nM to 1.03 μM) in vitro and in murine xenograft models (30 to 60 mg/kg via s.c.) in vivo via apoptosis induction.

Cell permeable: yes